

# ALEXANDER CAPITAL CL.P.

Global Equity Capital Markets Group

# Alexander Capital, L.P. Overview

ALEXANDER CAPITAL 🚱 L.P.

- Established in 1995
- Headquartered in New York City
- Full-service boutique brokerage operation
- Middle market corporate finance, and valuation services
- Retail managed in excess of \$1 billion of assets
- Alexander Capital, L.P. is a member of FINRA & SIPC
- Clearing agent is RBC Correspondent Services





# The Firm

## **Institutional Sales**

- Institutional sales and capital markets professionals dedicated to equity transactions
- Access to over 10,500 institutions of all sizes throughout the United States, Europe, Israel, Asia and South America
- Extensive deal and non-deal road-show platform



## **Retail Brokerage**

• Brokers provide asset management services, mutual funds, fixed income and equity investments



#### Jonathan Gazdak, Managing Director Head of Investment Banking

Mr. Gazdak is a Managing Director and the Head of Investment Banking. His concentration is in the Technology, Digital Media, Media and Entertainment industries, as well as Specialty Finance vehicles. He has worked on a broad range of transactions, including public equity and debt financings, restructurings, M&A and SPACs. Prior to Alexander, Mr. Gazdak was the head of the Technology Group at Aegis Capital. While at Aegis, he helped complete over 40 public / private financings and M&A transactions. Prior to Aegis, Mr. Gazdak was in the Media and Entertainment group at Oppenheimer & Co. Prior to his career in Investment Banking, Mr. Gazdak was an entrepreneur who owned and managed an International IT Consulting and Services firm for 10 years, selling it in 2005. Mr. Gazdak was a national board member and regional President of the TechServe Alliance. Mr. Gazdak received his MBA from Columbia Business School with Beta Gamma Sigma honors and from the University of Florida with a degree in Mechanical Engineering with honors.

#### Christopher Carlin, Head of Global Equity Capital Markets

Mr. Carlin has more than two decades of Wall Street experience and brings an extensive book of knowledge and investor relationships to Alexander Capital L.P. Mr. Carlin's institutional sales acumen is focused in the smallcap and midcap sector where between 2010-2015, he and his team originated, led and/or structured nearly 60 underwritten public offerings. In each financing, he and his team served as sole book-runner, lead manager, co-manager or syndicate member, and raised in excess of \$1 billion for their clients. Prior to joining Alexander Capital, Mr. Carlin was a Senior Vice President of Institutional Sales at Aegis Capital Corp. He began his career at Shearson Lehman as a member of the retail institutional sales team. From there he moved to the Institutional sales desk at Deutsche Bank Alex Brown where he was active in the small-mid cap sector. During his career Mr. Carlin has been involved in hundreds of public equity offerings spanning all industries. He is an active member of the Fordham alumni group.

We recognize that every capital raising situation is unique, and we take the extra time to assess the particular needs of each client to determine **the most effective strategy for raising capital,** devising appropriate structural and capital plans based on the client's individual goals.

- Christopher Carlin

Head of Global Equity Capital Markets

# Financial & General Advisory Services ALEXANDER CAPITAL @LR


- U.S. sole or dual listing
  - \* Listing on a national exchange; NASDAQ or NYSE
  - ✤ Listing on the OTCQX
- ADR Overview
- Jobs Act Overview
- Recent Transactions and Case Studies
- Marketing strategy including non-deal road shows
- Develop short and long-term goals focusing on corporate and shareholder value
- Comparable company and precedent transaction analysis







# **Institutional Services**



# **Global Equity Capital Markets**

Since November 2011 the Global Equity Capital Markets Group have originated, structured, underwritten and sold nearly **80 public offerings** (IPOs and Secondary Offerings) as a sole book-runner, lead manager, co-manager or syndicate member, raising in excess of **\$2.0 billion\***.



## Select, Recently-Closed Financings

# **Global Equity Capital Markets**

ALEXANDER CAPITAL 🖗 L.P.

### Select, Recently Closed Financings Continued



#### Adam Cichetti

Mr. Cichetti joined Alexander Capital L.P. in 2014. He is a member of the Institutional Sales desk in Global Equity Capital Markets. Prior to joining Alexander Capital, Mr. Cichetti was on the Institutional Sales desk at Aegis Capital Corp. In over a year at Aegis, he was involved in nearly 50 public offerings, raising in excess of \$800 M via IPO, Secondary, Bridge Loan, Convertible, PIPE, and Registered Direct offerings. Prior to Aegis Capital Corp., Mr. Cichetti was an Associate at venture capital firm Advanced Equities. He also has extensive trading experience and is a Series 7 and 66 licensed Registered Representative. Mr. Cichetti earned a BA in Economics from University at Albany - SUNY. He has lived in New York, Montana and Tennessee. Outside of work, he enjoys traveling, skiing and reading.

#### **Eric Thomson**

Mr. Thomson joined Alexander Capital L.P. in 2014 as part of the Institutional Sales Desk in their Global Equity Capital Markets Division. Prior to joining Alexander Capital, Mr. Thomson was on the Institutional Sales desk at Aegis Capital Corp. In the three and a half years at Aegis, Mr. Thomson was involved in nearly 60 public offerings, raising in excess \$850 M via IPO, Secondary, Bridge Loan, Convertible, PIPE, and Registered Direct offerings. Prior to joining the Capital Markets Desk, Mr. Thomson was the Director of Syndicate for Aegis. He started his career with Morgan Stanley's Global Wealth Management Division focusing on High Net Worth Individuals and Institutional Sales. Mr. Thomson holds his Series 7, 63 & 31 licenses and has earned his BS in Finance and Economics from Saint Joseph's University. He graduated as a member of Omicron Delta Epsilon, The International Honor Society for Economics. During his free time, he enjoys golfing, skiing, and traveling.

#### Jake Rodriques

Mr. Rodriques joined Alexander Capital in August of 2015 and currently works on the Institutional Sales Desk of the Global Equity Capital Markets Division. Prior to joining Alexander Capital, Mr. Rodriques was a student at Fordham University's Gabelli School of Business where he earned a BS in Marketing with a concentration in Entrepreneurship. Mr. Rodriques was a Captain of the Fordham Football Team and earned Academic and Athletic All Conference Honors in the Patriot League. He is a Series 7 and 63 licensed Registered Representative. Outside of work he enjoys, golf, traveling, and exercising.

# Capital Markets & Investment Banking ALEXANDER CAPITAL @ LP.

# **Our Key Strengths**

- Strong Relationships with a wide range of lenders, including:
  - Domestic and Commercial Banks
  - Insurance Companies
  - High-Net-Worth Individuals
  - Finance Companies
  - Institutional Investors
  - Specialized Pools of Capital

"Our funding sources place a great deal of trust in our ability to identify promising business opportunities"

- Providing access to capital via the public markets through a number of vehicles
- Significant experience advertising mid and large cap companies in a broad range of industries
- Mergers and Acquisitions
  - Finding the "right" buyer or seller
  - Price negotiation
  - Ensuring ongoing satisfaction of commitments made to the company's employees and community

# Sectors



## Lead, Joint-Bookrun and Co-Managed

#### ALEXANDER CAPITAL 🚱 L.P.

Recro Pharma, Inc.	Ceres, Inc.	Semler Scientific, Inc.	NephroGenex, Inc.	Biocept, Inc.
Recro Pharma	ceres	Semler Scientific	NephroGenex Innovative Therapies for Kidney Disease	.# Biocept
\$30,000,000	\$23,000,000	\$10,010,000	\$37,200,000	\$19,000,000
Initial Public Offering March 6, 2014	Follow-On Offering March 4, 2014	Initial Public Offering February 20, 2014	Initial Public Offering February 10, 2014	Initial Public Offering February 4, 2014
CytRx Corporation	SMTP, Inc.	Kips Bay Medical, Inc.	Akers Biosciences, Inc.	Intellicheck Mobilisa, Inc.
CytRx	SMTP email delivered	KIPS BAY	Akers Biosciences, Inc. Rapid Diagnostics, Real-Time Results	Intellicheck / Mobilisa
\$86,250,000	\$11,500,000	\$4,224,500	\$15,000,000	\$4,026,150
Follow-On Offering	Follow-On Offering	Follow-On Offering	US Initial Public Offering	Follow-On Offering
January 30, 2014	January 30, 2014	January 23, 2014	January 23, 2014	January 8, 2014
Fusion Telecommunications International, Inc.	Oramed Pharmaceuticals, Inc.	SuperCom Ltd.	Sorrento Therapeutics, Inc.	Opexa Therapeutics, Inc.
	oramed		SORRENTO THERAPEUTICS	OPEXA THERAPEUTICS
\$48,300,000	\$15,800,000	\$13,800,000	\$17,686,581	\$8,054,600
Private Placement	Registered Direct	Follow-On Offering	Block Trade	Follow-On Offering
December 31, 2013	December 24, 2013	December 19, 2013	December 19, 2013	December17, 2013

## Lead, Joint-Bookrun and Co-Managed

### ALEXANDER CAPITAL 🚱 L.P.



## Lead, Joint-Bookrun and Co-Managed

#### ALEXANDER CAPITAL 🚱 L.P.

Opexa Therapeutics, Inc.	Vuzix Corporation	Heat Biologics, Inc.	xG Technology, Inc.	Oramed Pharmaceuticals, Inc.
OPEXA THERAPEUTICS	VUZIX® View the Future	Heat Biologics	TECHNOLOGY, INC.	oramed
\$19,350,000	\$8,050,000	\$27,000,000	\$8,469,222	\$4,600,000
Follow-On Offering August 7, 2013	Follow-On Offering July 30, 2013	Initial Public Offering July 23, 2013	Initial Public Offering July 18, 2013	Registered Direct July 10, 2013
Echo Therapeutics, Inc.	Alcobra Ltd.	Stemline Therapeutics, Inc.	NeoStem, Inc.	Micronet Enertec Technologies, Inc.
C echo THERAPEUTICS	ALCOBRA PHARMA	<u>Stemline</u>	NeoStem	
\$12,500,000	\$25,000,000	\$69,000,000	\$11,500,000	\$9,325,000
Follow-On Offering	Initial Public Offering	Follow-On Offering	Follow-On Offering	Follow-On Offering
June 19, 2013	May 22, 2013	May 16, 2013	April 29, 2013	April 23, 2013
Cancer Genetics, Inc.	Rosetta Genomics, Ltd.	Five Oaks Investment Corp.	Hercules Technology Growth Capital	Oculus Innovative Sciences
CANCER GENETICS	\$5,900,000	Oaks Enclana Cap	TECHNOLOGY GROWTH CAPITAL	
\$6,900,000	Financial Advisor to	\$60,500,000	\$98,773,500	\$3,450,000
Initial Public Offering	Rosetta ATM Offering	Initial Public Offering	Follow-On Offering	Follow-On Offering
April 4, 2013	March 22, 2013	March 21, 2013	March 7, 2013	March 6, 2013

## Lead, Joint-Bookrun and Co-Managed

### ALEXANDER CAPITAL 🚱 L.P.

Professional Diversity Network, Inc.	Imprimis Pharmaceutics, Inc.	Echo Therapeutics, Inc.	Stemline Therapeutics, Inc.	Kips Bay Medical, Inc.
Professional Diversity Network the power of millions for the believed of only	IMPLIMACEUTICALS	echo <sup>®</sup> THERAPEUTICS	<u>Stemline</u>	KIPS BAY
\$21,000,000	\$11,109,000	\$11,758,750	\$38,152,910	\$6,500,000
Initial Public Offering	Follow-On Offering	Follow-On Offering	Initial Public Offering	Follow-on Offering
March 5, 2013	February 7, 2013	January 31, 2013	January 29, 2013	December 21, 2012
Echo Therapeutics, Inc.	Superconductor Technologies, Inc.	Northwest Biotherapeutics, Inc.	AspenBio Pharmaceuticals, Inc.	Comstock Mining Inc.
Ce echo THERAPEUTICS	<b>\$3,150,000</b>	Northwest Biotherapeutics \$13,800,000 Follow-On Offering	Aspen Bio Pharma	
\$3,496,000	Follow-On Offerings	Converted \$36,000,000	\$4,086,600	\$8,086,954
Follow-On Offering	November 20, 2012 &	Debt to Equity	Follow-On Offering	Follow-On Offering
December 20, 2012	December 7, 2012	December 7, 2012	November 15, 2012	November 13, 2012
Xplore Technologies Corp.	CytRx Corporation	Net Element International, Inc. merger with Cazador Acquisition Corporation	Ascent Solar Technologies, Inc.	Neuralstem, Inc.
TECHNOLOGIES.	CvtRx	Net Element	Ascent	🗱 NEURALSTEM INC.
\$10,000,000	CORPORATION		SOLAR	
Follow-on Offering				
Converted \$27,625,000	\$23,000,000	\$350,000,000	\$11,000,040	\$7,000,000
Preferred to Common	Follow-on Offering	Financial Adviser	Follow-On Offering	Registered Direct
October 25, 2012	October 18, 2012	October 2, 2012	September 19, 2012	September 13, 2012

Investment products are made available through Alexander Capital L.P.

Member FINRA (www.finra.org) & SIPC (www.sipc.org).

These documents are for informational purposes only. The information does not constitute a solicitation or an offer to buy or sell any security.

This information is confidential and intended solely for the use of Alexander Capital L.P. and the client or prospective client to whom it has been delivered. It is not to be reproduced or distributed to any person except to the client's professional advisor.

Before making an investment decision, you should carefully read the offering memorandum or prospectus which contains important disclosures regarding risks, fees, and expenses. Any third party information used in this document has been obtained from various published and unpublished sources considered to be reliable. However, Alexander Capital L.P. cannot guarantee its accuracy or completeness and thus, does not accept liability for any direct or consequential losses arising from its use.

Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate with changes in market conditions.



# ALEXANDER CAPITAL 🚱 L.P.

### **Corporate Office**

17 State St. 5th Floor New York, New York 10004

### **Christopher Carlin**

### Jonathan Gazdak

Head of Global Equity Capital Markets Phone: (646) 787-8890 <u>ccarlin@alexandercapitallp.com</u>

Managing Director, Head of Investment Banking Phone: (646) 787-8898 jgazdak@alexandercapitallp.com

Toll Free: (855) 288-ALEX Phone: (212) 687-5650 Fax: (212) 687-5649 www.alexandercapitallp.com

Member FINRA, SIPC